Hoffmann-La Roche: Leukemia, Myeloid, Acute trials
The registry lists 12 Leukemia, Myeloid, Acute studies with Hoffmann-La Roche as lead sponsor. 0 are open to participants now and 4 have results posted.
Phase 1 11Phase 2 2Phase 3 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid TumorsTerminatedNCT04029688Phase 1/2Results posted
- A Study Evaluating the Safety and Pharmacokinetics of Atezolizumab Administered in Combination With Hu5F9-G4 to Patients With Relapsed and/or Refractory Acute Myeloid LeukemiaTerminatedNCT03922477Phase 1Results posted
- A Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete RemissionTerminatedNCT03850535Phase 1/2Results posted
- A Study of Idasanutlin With Cytarabine Versus Cytarabine Plus Placebo in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)TerminatedNCT02545283Phase 3Results posted
- A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420.CompletedNCT04580121Phase 1
- A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine in Participants With Previously Untreated AML Unsuitable for Intensive Induction ChemotherapyCompletedNCT03298516Phase 1
- A Study Evaluating the Safety and Pharmacology of Atezolizumab Administered in Combination With Immunomodulatory Agents in Participants With Acute Myeloid Leukemia (AML)CompletedNCT02892318Phase 1
- A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic TherapyCompletedNCT02670044Phase 1
- A Study of RO6870810/TEN-010 in Participants With Acute Myeloid Leukemia and Myelodysplastic SyndromeCompletedNCT02308761Phase 1
- A Study of RO5503781 as a Single Agent or in Combination With Cytarabine in Participants With Acute Myelogenous LeukemiaCompletedNCT01773408Phase 1
- A Study of RO5429083 Alone or in Combination With Cytarabine in Patients With Acute Myelogenous LeukemiaCompletedNCT01641250Phase 1
- A Study of RO5045337 in Combination With Cytarabine in Patients With Acute Myelogenous LeukemiaCompletedNCT01635296Phase 1